ALPS Medical Breakthrough

Mirum Pharmaceuticals Launches $600M Convertible Senior Note Private Placement

UBS Maintains Buy Rating on CG Oncology with $90 Target Price Based on Bladder Cancer Therapy Data

LifeSci Capital Analyst Slutsky Reaffirms Buy Rating on SYRE with $103 Price Target

CG Oncology Plans Q4 BLA Submission for Bladder Cancer Drug Cretostimogene

CG Oncology Announces 92.3% Complete Response Rate in Bladder Cancer Drug Trial

Celcuity released FY2026 Q1 earnings on May 14 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9702 (forecast USD -1.0636)

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Celcuity Inc. Expands Gedatolisib Phase III Trial and Receives FDA Priority Review Designation

Mirum Pharmaceuticals Issues $600 Million Convertible Senior Notes Offering

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Apogee Therapeutic released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.0637 (forecast USD -1.0822)

CG Oncology released FY2026 Q1 earnings on May 8 (EST), actual revenue USD 1.083 M (forecast USD 453.03 K), actual EPS USD -0.7122 (forecast USD -0.5677)

Michael Thomas Henderson sold 80,000 shares of Spyre Therapeutics

Apellis Pharma released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 268.3 M (forecast USD 203.29 M), actual EPS USD 0.1461 (forecast USD -0.3526)

Newamsterdam Pharma released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 3.04 M (forecast USD 1.061 M), actual EPS USD -0.4 (forecast USD -0.4689)

Xenon Pharma released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 0 (forecast USD 1 M), actual EPS USD -1.1712 (forecast USD -1.1871)

Celcuity to Release FY2026 Q1 Earnings on May 14 After-Market EST, Forecast EPS USD -1.0636

Mirum Pharmaceuticals released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 159.88 M (forecast USD 153.05 M), actual EPS USD -13.4299 (forecast USD -0.3655)

Celcuity director Richard E. Buller sells 9,000 shares of company stock

Mirum Pharmaceuticals Reports 43% Increase in Net Product Sales in Q1 and Raises Full-Year Sales Guidance

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

RenovoRx Earnings Call Signals Commercial Inflection

RNXT

ARKG

LABU

SBIO

RenovoRx, Inc. reported record Q1 2026 revenue of $563,000, marking a 136% sequential growth. The company highlighted strong gross margins of 85.1% and an expanding commercial footprint with 16 active cancer centers. A pivotal Phase III trial is nearing full enrollment, and recent financing extends its cash runway into 2027. Despite impressive growth, management acknowledged execution risks and the need for consistent center conversions to sustain revenue growth. The company maintains a full-year revenue outlook of $3.0 million to $4.0 million.

Tip Ranks

RenovoRx

SPDR S&P Health Equip

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares US Pharma

iShares Biotechnology ETF

VG Health

Health Care Select Sector SPDR

iShares US Medical Devices

VanEck Biotech ETF

OBIO

B. Riley Financial has lowered its price target for Orchestra BioMed (NASDAQ:OBIO) from $12.00 to $10.00 while maintaining a 'buy' rating. This new target suggests a potential upside of 148.45% from the current price. Other analysts have varied opinions, with some reaffirming 'buy' ratings and others downgrading the stock. Currently, OBIO shares are trading at $4.03, with a market cap of $241.02 million.

Market Beat

Orchestra BioMed

Barclays

Virtu Finc

Bank of America

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Orchestra BioMed (NASDAQ:OBIO) Given New $10.00 Price Target at B. Riley Financial

CODX

Co-Diagnostics Inc. (CODX) has developed a Bundibugyo virus assay for rapid detection amid escalating Ebola outbreak alerts. Following WHO's emergency declaration, the company emphasizes the importance of decentralized diagnostics and rapid PCR testing. CEO Dwight Egan highlighted the need for quick mobilization in response to infectious diseases, shaped by lessons from COVID-19. The company is prepared for collaboration on future assay development. CODX shares are currently trading at $2.07, up 51.09%.

nasdaq

Co-Diagnostics

Nasdaq

Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up

ETON

IBBQ

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO, agreeing to pay $4.25 million in fixed fees and up to $4 million in sales milestones. Eton will share 55% of annual net sales up to $7 million and 50% above that. The agreement, effective from September 26, 2026, includes a term until March 31, 2032, with potential renewals. Symphony Health projects 2025 U.S. sales of $8.1 million.

TradingView

Eton Pharmaceuticals

Invesco Nasdaq Biotechnology ETF

Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share

TILE

MIRM

OKLO

TYRA

Top Wall Street analysts have initiated coverage on several companies with varying ratings. Oklo Inc (OKLO) received a Peer Perform rating, X-Energy Inc (XE) an Overweight rating with a $41 price target, Mirum Pharmaceuticals Inc (MIRM) an Outperform rating with a $145 target, Interface Inc (TILE) a Buy rating with a $36 target, and Tyra Biosciences Inc (TYRA) a Peer Perform rating.

benzinga_article

Interface

Mirum Pharmaceuticals

X-Energy

Oklo

Tyra Biosciences

This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

UCBJY

UCB announced positive results from the phase 3 BE BOLD trial, showing bimekizumab outperformed risankizumab in treating active psoriatic arthritis. At week 16, 49.1% of bimekizumab patients achieved ACR50 compared to 38.4% for risankizumab. Early improvements were noted as early as week 4. No new safety concerns were reported, although mild to moderate candida infections were more common with bimekizumab.

PharmaTimes

UCB S.A.

United Community Banks

UCB reports positive outcomes for bimekizumab in psoriatic arthritis

AMIX

A revolutionary technology has been developed that allows for minimally invasive transvascular access to nerve targets and tissues. This innovative method enables access through and beyond the lumen wall, providing a less invasive approach for procedures. This breakthrough is set to significantly improve treatment options for patients, with a success rate of over 90% in initial clinical trials. This technology is expected to benefit a wide range of medical fields and has the potential to transform minimally invasive procedures globally.

Unusual Whales

Autonomix Medical

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

ENTA

Enanta Pharmaceuticals Inc. (ENTA) is showcasing its investigational programs, Zelicapavir and EPS-3903, at the ATS International Conference. Zelicapavir is an oral antiviral targeting the N-protein for treating respiratory syncytial virus, disrupting viral replication directly.

rttnews

Enanta Pharma

Enanta Pharma's RSV Bet And Immunology Ambitions

Radnor Capital Management LLC increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 130.6% in Q4, now holding 6,000 shares valued at $1.65 million. Other institutional investors also raised their positions. West Pharmaceutical's stock opened at $304.31, with a market cap of $21.50 billion and a P/E ratio of 40.68. The company reported strong earnings, beating estimates, and announced a $1 billion stock repurchase plan.

West Pharmaceutical

Arcadian Asset

S&P 500

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

ADAG

Adagene's Chief Strategy Officer, Mickael Chane-Du, discussed the company's clinical strategy for its lead antibody program, ADG126, focusing on improving CTLA-4 inhibition. ADG126, a masked anti-CTLA-4 antibody, aims to enhance therapeutic efficacy in colorectal cancer, particularly in microsatellite-stable patients without liver metastases. The company is conducting a randomized Phase 2 trial to evaluate ADG126's effectiveness in combination with pembrolizumab, with results expected to guide future trials.

Adagene

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

BAYN

BAYRY

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

Bayer AG

Bayer

Bayer Aktiengesellschaft

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

Novo Nordisk AS

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bear 1X Shares

Eli Lilly

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

ALPS Medical Breakthrough(SBIO.US)

RenovoRx Earnings Call Signals Commercial Inflection

Orchestra BioMed (NASDAQ:OBIO) Given New $10.00 Price Target at B. Riley Financial

Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up

Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share

This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday